Latest Ratios: P/E Ratio 27.9x · EV/EBITDA 16.7x · ROE 20.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $38.9B | $36.6B | $24.9B | $11.7B | $10.1B | $8.9B | $10.6B | $10.7B | $15.7B | $19.3B | $34.8B |
| Enterprise Value | $52.8B | $50.4B | $39.7B | $28.6B | $28.9B | $30.2B | $34.8B | $36.1B | $42.9B | $50.8B | $69.6B |
| P/E Ratio → | 27.87 | 26.01 | — | — | — | 21.08 | — | — | — | — | 517.86 |
| P/S Ratio | 2.26 | 2.12 | 1.51 | 0.74 | 0.68 | 0.56 | 0.63 | 0.63 | 0.84 | 0.86 | 1.59 |
| P/B Ratio | 4.96 | 4.63 | 4.36 | 1.44 | 1.18 | 0.79 | 0.96 | 0.71 | 1.00 | 1.03 | 1.00 |
| P/FCF | 33.92 | 31.89 | 33.28 | 13.87 | 9.72 | 37.57 | 16.56 | 25.52 | 8.77 | 7.31 | 8.06 |
| P/OCF | 23.61 | 22.20 | 19.99 | 8.54 | 6.37 | 11.11 | 8.69 | 19.87 | 6.44 | 5.49 | 6.67 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.92 | 2.40 | 1.81 | 1.94 | 1.90 | 2.09 | 2.14 | 2.27 | 2.27 | 3.18 |
| EV / EBITDA | 16.70 | 15.97 | 52.52 | 18.04 | — | 9.90 | — | 28.19 | 209.16 | — | 19.09 |
| EV / EBIT | 24.46 | 23.58 | 11.78 | 70.64 | — | 9.80 | 11.39 | 13.28 | — | — | 50.76 |
| EV / FCF | — | 43.93 | 53.01 | 33.98 | 27.72 | 127.80 | 54.53 | 86.06 | 23.89 | 19.28 | 16.11 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.8% | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% | 44.6% | 44.0% | 48.4% | 54.1% |
| Operating Margin | 12.5% | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% | -8.7% | -78.1% | 9.8% |
| Net Profit Margin | 8.2% | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -24.0% | -5.9% | -11.4% | -72.7% | 1.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.7% | 20.7% | -23.7% | -6.7% | -24.7% | 3.7% | -30.5% | -6.5% | -12.4% | -60.5% | 1.0% |
| ROA | 3.5% | 3.5% | -4.0% | -1.3% | -5.3% | 0.8% | -7.4% | -1.7% | -3.3% | -19.9% | 0.4% |
| ROIC | 7.7% | 7.7% | -1.0% | 1.2% | -5.5% | 3.8% | -7.1% | -0.8% | -2.6% | -21.8% | 3.1% |
| ROCE | 8.0% | 8.0% | -1.0% | 1.4% | -6.4% | 4.6% | -8.8% | -1.0% | -3.3% | -27.5% | 3.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.20 | 2.20 | 3.16 | 2.48 | 2.51 | 2.09 | 2.39 | 1.82 | 1.83 | 1.73 | 1.02 |
| Debt / EBITDA | 5.50 | 5.50 | 23.91 | 12.71 | — | 7.70 | — | 21.38 | 141.05 | — | 9.81 |
| Net Debt / Equity | — | 1.75 | 2.58 | 2.08 | 2.18 | 1.89 | 2.19 | 1.68 | 1.72 | 1.68 | 0.99 |
| Net Debt / EBITDA | 4.38 | 4.38 | 19.55 | 10.67 | — | 6.99 | — | 19.83 | 132.36 | — | 9.54 |
| Debt / FCF | — | 12.04 | 19.73 | 20.10 | 18.00 | 90.23 | 37.96 | 60.54 | 15.12 | 11.97 | 8.05 |
| Interest Coverage | 2.34 | 2.34 | 3.58 | 0.39 | -2.40 | 3.46 | 4.05 | 2.84 | -1.88 | -19.66 | 1.03 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.92 |
| Quick Ratio | 0.80 | 0.80 | 0.75 | 0.69 | 0.72 | 0.79 | 0.65 | 0.66 | 0.63 | 0.58 | 0.65 |
| Cash Ratio | 0.26 | 0.26 | 0.26 | 0.26 | 0.24 | 0.20 | 0.17 | 0.14 | 0.12 | 0.05 | 0.05 |
| Asset Turnover | — | 0.42 | 0.42 | 0.36 | 0.34 | 0.33 | 0.33 | 0.29 | 0.31 | 0.32 | 0.24 |
| Inventory Turnover | 2.62 | 2.62 | 2.82 | 2.04 | 2.07 | 2.17 | 2.03 | 2.11 | 2.23 | 2.35 | 2.03 |
| Days Sales Outstanding | — | 78.45 | 67.49 | 78.51 | 90.39 | 104.11 | 100.37 | 122.68 | 112.71 | 116.23 | 125.37 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.5% | 0.1% | 4.7% | 3.7% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 396.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.6% | 3.8% | — | — | — | 4.7% | — | — | — | — | 0.2% |
| FCF Yield | 2.9% | 3.1% | 3.0% | 7.2% | 10.3% | 2.7% | 6.0% | 3.9% | 11.4% | 13.7% | 12.4% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.1% | 4.7% | 3.7% |
| Shares Outstanding | — | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.0B | $1.0B | $961M |
High Debt Refinancing Burden
According to current market data, Teva trades at a forward P/E of 15.19, which, when compared to historical volatility and peer multiples, suggests investors are pricing the equity as a distressed value play rather than a growth-oriented specialty pharmaceutical entity with a stable pipeline.
The disconnect between the trailing P/E of 27.68 and the forward multiple implies that the market anticipates significant earnings recovery, likely driven by the specialty portfolio. However, the elevated EV/EBITDA of 16.62 relative to peers suggests that the market remains skeptical of the company's ability to deleverage without further equity dilution or asset impairment.
Based on reported financial statements, Teva's ROIC has struggled to maintain positive momentum, fluctuating between a low of -0.7% in 2024Q1 and a peak of 3.0% in 2025Q3, indicating that the company is currently failing to generate returns that exceed its weighted average cost of capital.
The persistent weakness in ROIC is largely a function of the massive intangible asset base and goodwill carried on the balance sheet from past acquisitions. Until management can successfully pivot the product mix toward higher-margin specialty assets, the company will likely continue to face challenges in compounding capital effectively.
As reported in recent filings, Teva's cash conversion cycle remains inefficient, peaking at 147 days in 2024Q1 and only marginally improving to 108 days by 2026Q1, which highlights the structural difficulty of managing inventory and receivables within a complex, global generic manufacturing supply chain.
The high days inventory outstanding, which reached 182 days in 2023Q4, suggests that the company is carrying significant safety stock, likely to mitigate supply chain risks. This capital-intensive approach to inventory management directly constrains free cash flow and limits the company's ability to reduce its debt burden more aggressively.
Based on quarterly data, Teva's debt-to-EBITDA ratio has shown extreme volatility, spiking to 369.22 in 2024Q1 before moderating to 18.98 in 2026Q1, which underscores the precarious nature of the company's interest coverage and its ongoing vulnerability to refinancing risks in a high-rate environment.
While the reduction in total debt is a positive signal, the interest coverage ratio remains inconsistent, often dipping near or below parity during periods of operational stress. Investors should monitor the company's ability to maintain positive EBITDA growth, as any contraction could quickly jeopardize the sustainability of its current debt service obligations.
The P/E ratio is frequently misapplied to Teva's business model because it fails to account for the massive non-cash impairment charges and legal reserves that historically distort GAAP earnings, making the metric an unreliable indicator of the company's true underlying cash-generating capacity.
Analysts should instead focus on EV/EBITDA or free cash flow yield, as these metrics better capture the operational reality of a company burdened by significant debt and lumpy litigation-related outflows. Relying on P/E ignores the structural reality that Teva's equity value is currently a residual claim on cash flows after substantial debt servicing and legal settlement requirements.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TEVA stock.
Teva Pharmaceutical Industries Limited's current P/E ratio is 27.9x. The historical average is 31.3x. This places it at the 55th percentile of its historical range.
Teva Pharmaceutical Industries Limited's current EV/EBITDA is 16.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.0x.
Teva Pharmaceutical Industries Limited's return on equity (ROE) is 20.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 4.6%.
Based on historical data, Teva Pharmaceutical Industries Limited is trading at a P/E of 27.9x. This is at the 55th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Teva Pharmaceutical Industries Limited has 51.8% gross margin and 12.5% operating margin. Operating margin between 10-20% is typical for established companies.
Teva Pharmaceutical Industries Limited's Debt/EBITDA ratio is 5.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.